# Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas

> **NCT01216839** · PHASE2 · UNKNOWN · sponsor: **Sidnei Epelman** · enrollment: 20 (estimated)

## Conditions studied

- Refractory or Relapsed RMS and Soft Tissue Sarcomas

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01216839
- **Lead sponsor:** Sidnei Epelman
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-03
- **Primary completion:** 2013-10
- **Final completion:** 2013-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2013-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01216839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01216839, "Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT01216839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*